Published in Dig Dis on August 09, 2011
Effectiveness of Drug Eluting TACE in Primary HCC | NCT04048317
Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) (2015) 1.88
Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol (2015) 1.78
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer (2012) 1.36
Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol (2013) 1.35
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer (2014) 1.35
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer (2013) 1.21
Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol (2014) 1.17
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol (2014) 1.12
Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 1.10
Recent Advances in Tumor Ablation for Hepatocellular Carcinoma. Liver Cancer (2015) 1.08
Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china. Liver Cancer (2013) 1.05
Treatment algorithms for managing hepatocellular carcinoma. J Clin Exp Hepatol (2014) 1.03
Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res (2014) 1.03
Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma. Liver Cancer (2012) 1.02
Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol (2015) 1.02
Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol (2012) 1.01
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer (2013) 1.00
Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer (2012) 0.98
Locoregional Therapy for Hepatocellular Carcinoma. Liver Cancer (2015) 0.97
Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer (2013) 0.97
Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97
The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size. World J Surg (2015) 0.96
Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer (2015) 0.96
Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol (2013) 0.96
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer (2015) 0.95
Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. Radiat Oncol J (2014) 0.93
New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer (2012) 0.92
Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan. J Cancer (2014) 0.91
New advances in hepatocellular carcinoma. World J Hepatol (2016) 0.91
Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer (2013) 0.91
Factors associated with compliance with recommendations for liver cancer screening in Korea: a nationwide survey in Korea. PLoS One (2013) 0.91
Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol (2014) 0.90
Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol (2013) 0.90
High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter. Surg Today (2013) 0.89
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol (2015) 0.89
Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. PLoS One (2014) 0.89
Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging. Liver Cancer (2012) 0.88
Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis. BMC Health Serv Res (2012) 0.88
Liver transplantation for advanced hepatocellular carcinoma in patients with Child-Pugh A and B. Surg Today (2015) 0.87
Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol (2014) 0.87
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol (2016) 0.87
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs (2015) 0.87
Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. World J Gastroenterol (2012) 0.87
Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res (2015) 0.87
Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol (2015) 0.85
Prognosis of small hepatocellular nodules detected only at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging as hypointensity in cirrhosis or chronic hepatitis. Eur Radiol (2014) 0.85
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther (2016) 0.84
The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. J Gastroenterol (2012) 0.84
Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer (2013) 0.84
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer (2016) 0.83
Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol (2016) 0.83
Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol (2013) 0.83
Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol (2012) 0.83
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Invest New Drugs (2016) 0.83
Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer (2012) 0.83
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs (2015) 0.82
A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. PLoS One (2015) 0.82
Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol (2013) 0.82
Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol (2015) 0.82
Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdom Radiol (2016) 0.82
Radiation therapy has been shown to be adaptable for various stages of hepatocellular carcinoma. World J Gastroenterol (2015) 0.82
Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. PLoS One (2014) 0.82
A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiat Oncol (2013) 0.81
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One (2015) 0.81
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine (Baltimore) (2016) 0.81
Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol (2014) 0.81
Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol (2015) 0.81
Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol (2015) 0.81
Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology. Medicine (Baltimore) (2015) 0.81
Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol (2015) 0.81
Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer (2015) 0.80
Role of surgical resection for hepatocellular carcinoma based on Japanese clinical guidelines for hepatocellular carcinoma. World J Hepatol (2015) 0.80
Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol (2014) 0.80
Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer (2015) 0.80
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol (2016) 0.80
Time trends of clinical characteristics in hepatocellular carcinoma patients with chronic hepatitis B virus infection: A field survey between 2000 and 2012. Mol Clin Oncol (2014) 0.80
Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage (Barcelona Clinic Liver Cancer stage-B or stage-C) hepatocellular carcinoma: multicenter phase-II clinical study. Int J Clin Oncol (2014) 0.80
Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. Clin Drug Investig (2015) 0.80
National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer (2016) 0.79
Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol (2016) 0.79
Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer (2015) 0.79
Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer (2015) 0.79
Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. World J Gastroenterol (2013) 0.79
Contrast-enhanced ultrasound: Improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment. World J Gastroenterol (2014) 0.79
Clinical impact of ultrasound-related techniques on the diagnosis of focal liver lesions. Liver Cancer (2012) 0.79
Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI. Liver Cancer (2015) 0.79
Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. J Gastroenterol (2015) 0.79
Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci (2013) 0.79
State-of-the-art imaging of liver fibrosis and cirrhosis: A comprehensive review of current applications and future perspectives. Eur J Radiol Open (2015) 0.78
Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. J Gastrointest Surg (2016) 0.78
Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol (2014) 0.78
Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther (2013) 0.78
Current status of multimodal & combination therapy for hepatocellular carcinoma. Indian J Med Res (2012) 0.78
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. Liver Cancer (2016) 0.78
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. Int J Clin Oncol (2015) 0.78
Expression of Phosphorylated AMP-Activated Protein Kinase Predicts Response to Transarterial Chemoembolization in Postoperative Cases of Hepatocellular Carcinoma. Medicine (Baltimore) (2016) 0.77
Comparative analysis of Laparoscopic versus open surgical radiofrequency ablation for malignant liver tumors. Korean J Hepatobiliary Pancreat Surg (2014) 0.77
Contrast-Enhanced Ultrasound for the Characterization of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Liver Cancer (2015) 0.77
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med (2002) 4.25
Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13
One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (2013) 3.27
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (2011) 2.81
Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl (2014) 2.77
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer (2009) 2.54
Fluorescent cholangiography using indocyanine green for laparoscopic cholecystectomy: an initial experience. Arch Surg (2009) 2.48
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology (2008) 2.40
Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. Ann Surg (2015) 2.36
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res (2004) 2.34
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Portal uptake function in veno-occlusive regions evaluated by real-time fluorescent imaging using indocyanine green. J Hepatol (2012) 2.27
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun (2002) 2.13
Low papillary structure in lepidic growth component of lung adenocarcinoma: a unique histologic hallmark of aggressive behavior. Hum Pathol (2013) 2.13
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Regeneration and function of hemiliver graft: right versus left. Surgery (2006) 2.12
Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol (2008) 2.06
Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections. World J Surg (2004) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg (2003) 2.01
Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends (2010) 2.01
Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg (2003) 2.00
Laparoscopic segmentectomy of the liver: from segment I to VIII. Ann Surg (2012) 1.99
Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol (2003) 1.94
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res (2008) 1.91
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg (2009) 1.87
Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology (2003) 1.87
Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology (2003) 1.85
IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. Am J Surg Pathol (2009) 1.82
EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology (2003) 1.82
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg (2007) 1.82
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology (2013) 1.81
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol (2010) 1.79
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist (2012) 1.76
Mechanistic background and clinical applications of indocyanine green fluorescence imaging of hepatocellular carcinoma. Ann Surg Oncol (2013) 1.76
Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology (2009) 1.75
Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer (2003) 1.75
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol (2005) 1.74
Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc Natl Acad Sci U S A (2002) 1.73
Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer (2005) 1.73
Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol (2006) 1.72
Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells (2008) 1.68
Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery (2003) 1.67
Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol (2008) 1.65
Spontaneous hemothorax in neurofibromatosis treated with percutaneous embolization. Cardiovasc Intervent Radiol (2007) 1.64
Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl (2012) 1.64
Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol (2009) 1.63
Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol (2008) 1.63
Peliosis hepatis: spectrum of imaging findings. AJR Am J Roentgenol (2006) 1.62
Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. Radiology (2010) 1.61
G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol (2008) 1.60
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology (2006) 1.60
Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res (2002) 1.60
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis (2007) 1.60
Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res (2002) 1.59
Refinement of venous reconstruction using cryopreserved veins in right liver grafts. Liver Transpl (2004) 1.59